Gastrointestinal Cancer | Specialty

Genetic Testing Recommended for All Patients With Pancreatic Cancer

April 12th 2019

In a provisional clinical opinion, an expert panel convened by the American Society of Clinical Oncology has recommended that patients with pancreatic cancer undergo assessment of risk for hereditary syndromes that contribute to higher likelihood of pancreatic cancer.

Dr. Fakih on the Use of Regional Therapy in Colorectal Cancer

April 11th 2019

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the use of regional therapy in the treatment of patients with colorectal cancer (CRC).

Dr. Tempero on Importance of Germline Testing in Pancreatic Cancer

April 11th 2019

Margaret A. Tempero, MD, director of the Pancreas Center and the Rombauer Family Distinguished Professor in Pancreas Cancer Clinical and Translational Science at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the importance of germline testing in pancreatic cancer.

Genetic Testing Essential to Advancing Pancreatic Cancer Paradigm

April 9th 2019

Margaret A. Tempero, MD, discusses the impact of FOLFIRINOX in the treatment of patients with metastatic pancreatic cancer and sheds light on the importance of molecular profiling in the space.

Dr. Marshall on HER2 Amplification in Colorectal Cancer

April 8th 2019

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses HER2 amplification in colorectal cancer (CRC).

Dr. Kim on Role of Frontline Immunotherapy in Advanced HCC

April 8th 2019

Richard Kim, MD, assistant professor of oncology, University of South Florida College of Medicine, medical oncologist, Department of Gastrointestinal Oncology, Moffitt Cancer Center, discusses the role of frontline immunotherapy in patients with advanced hepatocellular carcinoma.

Pancreatic Cancer Field Pushes Forward Following Pivotal Trial Readouts

April 8th 2019

Jordan D. Berlin, MD, sheds light on current and future directions in the field of locally advanced pancreatic cancer.

Lutathera Fills Unmet Need in NETs, Role of Radiation Expands Across GI Cancers

April 5th 2019

Derek R. McHaffie, MD, discusses the role of radiation therapy in the treatment of gastrointestinal cancers and the impact of radionuclide therapy in patients with neuroendocrine tumors.

Dr. Lee on Tailoring Treatment to Tumor Sidedness in mCRC

April 4th 2019

Michael S. Lee, MD, assistant professor of medicine, Department of Molecular Therapeutics, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment to tumor sidedness in patients with metastatic colorectal cancer.

Immunotherapy Shakes Up Gastric/GEJ Cancer Space, Alongside Angiogenic, Cytotoxic Agents

April 4th 2019

J. Stuart Salmon, MD, highlights first-, second-, and third-line treatment options for patients with gastric and gastroesophageal cancer following recent clinical trial findings and regulatory approvals.

Novel Therapies Lower Symptom Burden, Improve Survival in NETs

April 4th 2019

Kunal C. Kadakia, MD, highlight key takeaways from the the PROMID, CLARINET, and NETTER-1 trials and explains how their findings have been applied to clinical practice.

Therapeutic Options Available for Pancreatic Cancer, HCC Lead to New Challenges

April 3rd 2019

Jimmy J. Hwang, MD, sheds light on updates in both metastatic pancreatic cancer and advanced hepatocellular carcinoma that have created new complexities for researchers.

Dr. Berlin on Potential Targets in Pancreatic Cancer

April 3rd 2019

Jordan D. Berlin, MD, Ingram Professor of Cancer Research, professor of medicine, VICC associate director for clinical research strategy, director, Phase I Program, gastrointestinal malignancies, clinical trials, Department of Medicine, Vanderbilt University Medical Center, discusses potential targets in pancreatic cancer.

Dr. Salem on the Results of the MyPathway Trial in mCRC

April 3rd 2019

Mohamed E. Salem, MD, a medical oncologist at Levine Cancer Institute, Atrium Health, discusses the results of the MyPathway trial in metastatic colorectal cancer (mCRC).

Dr. Patel on Benefit of Ipilimumab/Nivolumab Combo in High-Grade Neuroendocrine Carcinoma

April 3rd 2019

Sandip Patel, MD, associate professor of medicine at the University of California San Diego School of Medicine, discusses the benefit of the immune checkpoint inhibitor combination of ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with rare, high-grade neuroendocrine tumors.

Rucaparib Maintenance Shows Early Efficacy in Pancreatic Cancer

April 2nd 2019

Maintenance therapy with rucaparib maintained disease control and was well tolerated in patients with platinum-sensitive, advanced BRCA1/2- or PALB2-mutant pancreatic cancer, according to preliminary interim findings of a single-arm, phase II trial.

Association Between BMI and Pancreatic Cancer Mortality

April 2nd 2019

Eric J. Jacobs, PhD, cancer epidemiologist and strategic director of pharmacoepidemiology, American Cancer Society, discusses results from a prospective cohort study examining the association between BMI and pancreatic cancer mortality.

Dr. Roychowdhury on FGFR Inhibitor Infigratinib in Cholangiocarcinoma

April 1st 2019

Sameek Roychowdhury, MD, PhD, associate professor of medical oncology, the Ohio State University Comprehensive Cancer Center, discusses a phase II study with infigratinib (BGJ398) in patients with cholangiocarcinoma.

Novel CAR Therapy Shows Promising Early Signals in Pancreatic Cancer

March 31st 2019

Although CAR T-cell therapy has not yet proved effective against solid tumors, a novel CAR that targets mesothelin proteins expressed in pancreatic cancer is showing early signs of activity.

Refinement of Techniques and the Future of mCRC

March 29th 2019